Lantheus (NASDAQ:LNTH) Price Target Cut to $73.00 by Analysts at JMP Securities

Key Points

• JMP Securities has lowered its target price for Lantheus (NASDAQ:LNTH) from $112.00 to $73.00, indicating a potential upside of 36.19% from the current share price.
• Despite the cut in target price, Lantheus maintains a consensus rating of "Moderate Buy" with an average price target of $114.50 among various analysts.
• Lantheus reported earnings of $1.53 per share for the last quarter, missing expectations by $0.11, with revenue of $372.76 million, which was slightly below analysts' expectations.

Lantheus (NASDAQ:LNTH - Get Free Report) had its price target decreased by research analysts at JMP Securities from $112.00 to $73.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has a "market outperform" rating on the medical equipment provider's stock. JMP Securities' target price would suggest a potential upside of 31.53% from the stock's current price.

Other analysts have also issued reports about the company. Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. William Blair reaffirmed a "market perform" rating on shares of Lantheus in a report on Wednesday, July 16th. Truist Financial lowered their target price on Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. B. Riley decreased their target price on Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a research report on Monday, June 23rd. Finally, Mizuho decreased their target price on Lantheus from $120.00 to $70.00 and set an "outperform" rating on the stock in a research report on Thursday. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $114.50.

Lantheus Price Performance

Shares of NASDAQ:LNTH traded down $1.70 on Thursday, reaching $55.50. 1,093,185 shares of the company traded hands, compared to its average volume of 1,128,853. Lantheus has a fifty-two week low of $47.25 and a fifty-two week high of $118.21. The company's 50 day moving average is $76.31 and its 200-day moving average is $86.78. The stock has a market capitalization of $3.77 billion, a PE ratio of 14.79 and a beta of 0.14. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.29 and a quick ratio of 4.07.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.65 by ($0.08). The business had revenue of $378.05 million during the quarter, compared to analysts' expectations of $389.69 million. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. Lantheus's revenue for the quarter was down 4.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.80 EPS. As a group, analysts anticipate that Lantheus will post 6.01 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Mary Anne Heino sold 26,066 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the transaction, the director owned 318,650 shares in the company, valued at $24,481,879.50. The trade was a 7.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 2.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Signaturefd LLC raised its position in Lantheus by 36.5% in the 1st quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 116 shares during the last quarter. Quarry LP grew its holdings in Lantheus by 2,350.0% during the 1st quarter. Quarry LP now owns 490 shares of the medical equipment provider's stock worth $48,000 after acquiring an additional 470 shares during the period. Hughes Financial Services LLC acquired a new stake in Lantheus during the 1st quarter worth $81,000. UMB Bank n.a. grew its holdings in Lantheus by 68.2% during the 1st quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider's stock worth $92,000 after acquiring an additional 381 shares during the period. Finally, Parkside Financial Bank & Trust grew its holdings in Lantheus by 20.2% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,264 shares of the medical equipment provider's stock worth $103,000 after acquiring an additional 212 shares during the period. Institutional investors own 99.06% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.